Flagship-Backed Generate Biomedicines Seeks $425 Million in IPO

Generate Biomedicines Inc., a biotechnology firm using artificial intelligence in drug development, is seeking to raise as much as $425 millon in an initial public offering, as listing activity in the sector picks up sharply....

Redirecting to full article...